Edg receptor agonists
US7479504B2 · kind B2 · utility
13Cited by
4References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 15, 2003 |
| Grant date | Jan 20, 2009 |
| Priority date | — |
| Expiry date | Jun 17, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/65586
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention encompasses compounds of Formula 1: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.